Top 3 advancements in oncology: February 2022
February has been a busy month for the National Institute for Health and Care Excellence in the UK! It has provided guidance recommending both a PARP inhibitor and a tyrosine kinase inhibitor, as well as endorsing four new devices for safer prostate cancer diagnosis. Find out more by checking out the summary below. Freehand needle positioning device Approved: 15 Feburary 2022 Approving body: NICE Indication: Prostate cancer NICE has recommended four new freehand needle positioning devices to help guide local anesthetic transperineal (LATP) prostate biopsies this month. These are; PrecisionPoint, EZU-PA3U device, Trinity Perine Grid, and UA1232 device. These devices...
